A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.

Both BMS and J&J touted positive data for their multiple myeloma drugs at ASCO 2026.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.